BiotechTube
Home/Enlila/John Doe
JD

John Doe

CEO

Enlila

Therapeutic Areas

MetabolismAgingObesityCardiovascular DiseaseDiabetes

Enlila Pipeline

DrugIndicationPhase
ENL‑101Obesity‑related inflammationPreclinical
ENL‑102Non‑alcoholic fatty liver diseasePreclinical
ENL‑103AtherosclerosisPreclinical

Leadership Team at Enlila

JS
Jane Smith
CSO
View full Enlila profile